Home » Stocks » Forma Therapeutics

Forma Therapeutics Holdings, Inc. (FMTX)

Stock Price: $49.50 USD 5.77 (13.19%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.04B
Revenue (ttm) 10.82M
Net Income (ttm) n/a
Shares Out 41.12M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $49.50
Previous Close $43.73
Change ($) 5.77
Change (%) 13.19%
Day's Open 43.44
Day's Range 42.83 - 52.09
Day's Volume 297,688
52-Week Range 31.45 - 52.09

More Stats

Market Cap 2.04B
Enterprise Value 1.62B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 41.12M
Float 32.00M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 999,717
Short Ratio 4.53
Short % of Float 1.84%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 188.09
PB Ratio 4.35
Revenue 10.82M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 414.30M
Net Cash / Share 10.08
Gross Margin -99.42%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(13.64% upside)
Current: $49.50
Target: 56.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-38.72%-
Gross Profit101164
Operating Income-40.459.69
Net Income-34.795.29
Shares Outstanding10.9010.90
Earnings Per Share-4.93-0.04
Operating Cash Flow-34.49-133
Capital Expenditures-0.53-3.39
Free Cash Flow-35.02-136
Cash & Equivalents173152
Net Cash / Debt173152
Book Value18.25-48.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Forma Therapeutics Holdings, Inc.
Country United States
Employees 80
CEO Frank D. Lee

Stock Information

Ticker Symbol FMTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FMTX
IPO Date June 19, 2020


Forma Therapeutics Holdings, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.